ARCA biopharma, Inc. (ABIO) is a publicly traded company in the Unknown sector. Across all available filings, 35 corporate insiders have executed 173 transactions totaling $22.0M, demonstrating a bearish sentiment with -$8.5M in net insider flow. The most recent transaction on Aug 16, 2024 involved a purchase of 428 shares valued at $1.3K.
No significant insider buying has been recorded for ABIO in the recent period.
No significant insider selling has been recorded for ABIO in the recent period.
Based on recent SEC filings, insider sentiment for ABIO is bearish with an Insider Alignment Score of 31/100 and a net flow of -$8.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ARCA biopharma, Inc. (ABIO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 35 insiders are actively trading ABIO stock, having executed 173 transactions in the past 90 days. The most active insider is Funds, Lp Funicular (Executive), who has made 3 transactions totaling $3.5M.
Get notified when executives and directors at ABIO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 16, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 428 | $2.98 | $1.3K | |
| Aug 16, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 5,390 | $2.93 | $15.8K | |
| Jul 25, 2024 | Group Plc Janus Henderson | Executive | Purchase | 30,227 | $3.05 | $92.2K | |
| Jul 24, 2024 | Group Plc Janus Henderson | Executive | Purchase | 165,000 | $3.20 | $528.0K | Large |
| Jul 24, 2024 | Group Plc Janus Henderson | Executive | Purchase | 17,800 | $3.18 | $56.6K | |
| Jul 24, 2024 | Group Plc Janus Henderson | Executive | Purchase | 7,056 | $3.16 | $22.3K | |
| Jul 11, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 94,537 | $3.45 | $326.2K | |
| Jul 10, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 33,500 | $3.46 | $115.9K | |
| Jul 10, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 21,963 | $3.46 | $76.0K | |
| Jul 9, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 16,917 | $3.43 | $58.0K | |
| Jul 8, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 17,600 | $3.54 | $62.3K | |
| Jul 8, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 29,892 | $3.41 | $101.9K | |
| Jul 5, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 5,000 | $3.41 | $17.1K | |
| Jul 5, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 23,326 | $3.43 | $80.0K | |
| Jul 3, 2024 | Biotech Innovation Master Fund Ltd Janus Henderson | Executive | Purchase | 166,042 | $3.55 | $589.4K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 82 | $15.2M | 56.9% |
Purchase(P) | 54 | $6.8M | 25.3% |
Exercise (Options)(X) | 1 | $3.5M | 13.2% |
Award(A) | 17 | $1.2M | 4.5% |
Other(J) | 16 | $29.5K | 0.1% |
Exercise(M) | 2 | $690 | 0.0% |
Conversion(C) | 1 | $0 | 0.0% |
Insider selling pressure at ARCA biopharma, Inc. has increased, with 35 insiders executing 173 transactions across all time. Total sales of $15.2M significantly outpace purchases of $6.8M, resulting in a net outflow of $8.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.